Cargando…

Molecular heterogeneity of breast cancer: implications for treatment and clinical trial design

Detalles Bibliográficos
Autor principal:	Pusztai, L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284868/ http://dx.doi.org/10.1186/bcr2265

Ejemplares similares

Gene pathways associated with prognosis and chemotherapy sensitivity in different molecular subtypes of breast cancer
por: Pusztai, L
Publicado: (2011)

Molecular heterogeneity of luminal breast cancer
por: Loi, S
Publicado: (2011)

Insulin resistance in breast cancer: relevance and clinical implications
por: Goodwin, PJ
Publicado: (2011)

Breast tumor heterogeneity: causes and consequences
por: Polyak, K, et al.
Publicado: (2009)

Gene expression profile-based predictors of response to chemotherapy
por: Pusztai, L
Publicado: (2005)

Methods for gene expression profiling in clinical trials for breast cancer
por: Paik, S
Publicado: (2005)

The evolution of and challenges in defining the clinical endpoint in tuberculosis treatment trials with non-inferiority designs
por: Phillips, Patrick PJ, et al.
Publicado: (2011)

Using adaptive designs for decision making within the optima trial: optimal personalized treatment of early breast cancer using multi-parameter tests
por: Dunn, Janet, et al.
Publicado: (2013)

The challenges in translating present knowledge of the molecular biology of breast cancer into clinical use
por: Davidson, N
Publicado: (2005)

An adaptive biomarker strategy clinical trial design
por: Wason, James, et al.
Publicado: (2013)

Clinical trials in breast cancer; do we have the right approaches?
por: Lønning, PE
Publicado: (2000)

Two molecular cytogenetic views of breast cancer
por: Gray, J, et al.
Publicado: (2000)

Metabolic heterogeneity in cancer
por: DeBerardinis, Ralph J
Publicado: (2014)

Adaptive enrichment in biomarker-stratified clinical trial design
por: Parashar, Deepak, et al.
Publicado: (2013)

Design of RESILIENCE: a phase 3 trial comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic HER2-negative breast cancer
por: Baselga, J, et al.
Publicado: (2011)

Adolescents' perception of coercive treatment: conclusions and clinical implications
por: Engström, Ingemar
Publicado: (2007)

Optimal design for multi-arm multi-stage clinical trials
por: Wason, James MS, et al.
Publicado: (2011)

Longitudinal mediation in the PACE randomised clinical trial of rehabilitative treatments for chronic fatigue syndrome: modelling and design considerations
por: Goldsmith, Kimberley, et al.
Publicado: (2015)

Gene amplification in breast cancer – looking for the molecular mechanisms
por: Kovalenko, Sergei
Publicado: (2010)

Magnetic resonance imaging in breast cancer: results of the COMICE trial
por: Turnbull, L
Publicado: (2008)

Clinical breast cancer and estrogen
por: Chew, HK
Publicado: (2003)

Molecular distinctions among ERBB2-overexpressing breast cancers
por: Jeffrey, SS
Publicado: (2005)

How pre-trial qualitative research can change proposed RCT design: a case study and implications for future research
por: Rooshenas, Leila, et al.
Publicado: (2015)

Developing new treatments for breast cancer
por: Lane, D
Publicado: (2004)

Modelling residual disease volume and re-growth rates from response durations to aid in cancer trial design, interpretation and analysis, with a particular focus on breast cancer
por: Gregory, Walter, et al.
Publicado: (2013)

Exploring meaning of participation in a clinical trial in a developing country setting: implications for recruitment
por: Reynolds, Joanna, et al.
Publicado: (2011)

OA12 Dactylitis in PsA: aetiology, clinical significance, & treatment implications
por: Melville, Andrew
Publicado: (2022)

Molecular approaches to understanding pregnancy-induced protection against breast cancer
por: Blakely, CM, et al.
Publicado: (2005)

Molecular profiling of early breast cancer in relation to detection of micrometastases and outcome
por: Naume, B, et al.
Publicado: (2005)

Molecular control of apoptosis in the breast
por: Streuli, C, et al.
Publicado: (2000)

Using a Bayesian approach with reverse philosophy to design clinical trials in rare diseases
por: Billingham, Lucinda, et al.
Publicado: (2013)

Validated scoring of halogen bonding in molecular design
por: Zimmermann, MO, et al.
Publicado: (2014)

Assessing the presence of selection bias in meta-analyses of randomised trials using baseline heterogeneity
por: Clark, Laura, et al.
Publicado: (2013)

Bisphosphonates in the adjuvant treatment of early breast cancer
por: Gnant, M
Publicado: (2009)

Minimising surgical treatment of early breast cancer
por: Rainsbury, R
Publicado: (2008)

Minimising oncological treatment of early breast cancer
por: Yarnold, J
Publicado: (2008)

Molecular characterization of mutations in galactosemia genes: structural and functional implications
por: Singh, R, et al.
Publicado: (2014)

Design, conduct and challenges of a clinical trial utilizing elastic light scattering spectroscopy in the thyroid
por: Rosen, Jennifer, et al.
Publicado: (2010)

Molecular characteristics of inherited breast tumors
por: Borg, Å, et al.
Publicado: (2000)

Evaluation of methods to adjust for treatment switching in clinical trials
por: Fox, Richard, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_4um26ci0dutvrrvaqgrvtno35d